drugset / Trial / NCT00679250

To Evaluate Adenosine Monophosphate and Allergen Challenge in Allergic Rhinitis

NCT00679250 ↗

Phase 4 Completed 25 enrolled Brian J Lipworth
RandomizedCrossoverTriple-blindTreatment

Summary

Allergic rhinitis is a common condition characterize by inflammation of the upper airways. Third generation antihistamines have been demonstrated effective in the treatment of this condition. Allergen challenge can be use to assess the effects of drugs in allergic rhinitis, adenosine monophosphate may also be used as a means to investigate these effects but as yet its effects have yet to be compared to allergen challenge. We intend to compare the effects of levocetirizine at a single dose of 5mg on allergen and AMP challenge compared to placebo in a double blind cross-over study. The study will include 20 patients with allergic rhinitis. Each patient will have allergen and AMP challenge on placebo and active treatment. The primary outcome variable will be the change in concentration of AMP/Allergen required to produce a 20% drop in nasal flow as manifest by peak nasal inspiratory flow. A 1 doubling dose change in concentration of challenge medium to cause a 20% drop in nasal flow will be deemed significant. We will also measure time to recovery after both challenges. AMP challenge is a safe alternative to allergen challenge and does not have the risk of anaphylaxis.

Timeline

Start
2005-11
Primary completion
2006-12
Completion
2006-12

Outcome

Mixed primary results

paper The primary end-point was the provocative concentration of AMP or allergen causing a 20% drop in the PNIF (PC(20)). PMID 19187327 ↗

paper PC(20) improvement amounted to a 1.26 (95% CI 0.16, 2.35) and 0.16 (95% CI -0.41, 0.73) doubling-dilution shifts for allergen and AMP challenges, respectively. PMID 19187327 ↗

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Levocetirizine Unknown 5 mg —

Indications